In a report released yesterday, Lawrence Keusch from Raymond James maintained a Buy rating on Becton Dickinson (BDX). The company’s shares closed last Wednesday at $256.82.
According to TipRanks.com, Keusch is a 4-star analyst with an average return of 9.9% and a 72.1% success rate. Keusch covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Baxter International, and Intuitive Surgical.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Becton Dickinson with a $286.50 average price target, implying an 11.6% upside from current levels. In a report issued on February 4, Piper Sandler also maintained a Buy rating on the stock with a $280.00 price target.
See today’s analyst top recommended stocks >>
Based on Becton Dickinson’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $5.32 billion and net profit of $1 billion. In comparison, last year the company earned revenue of $4.23 billion and had a net profit of $278 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Becton, Dickinson & Co. is a medical technology company. The firm engages in the development, manufacture and sale of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. It operates through the following segments: BD Medical, BD Life Sciences and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect infectious diseases, healthcare-associated infections and cancers. The BD Interventional segment provides vascular, urology, oncology and surgical specialty products to hospitals, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via Homecare business. The company was founded in 1897 and is headquartered in Franklin Lakes, NJ.
Read More on BDX:
